Suggestions
Avery Posey, Jr., Ph.D.
Assistant Professor at University of Pennsylvania School of Medicine
Avery Posey, Jr., Ph.D. is an Assistant Professor at the University of Pennsylvania School of Medicine, specializing in cancer immunotherapy research.1 He has held this position since July 2019, focusing on CAR-T cell development for solid tumor treatment, T cell exhaustion, and glycotargets.1
Career and Education
Dr. Posey's academic journey includes:
- A postdoctoral fellowship in Cancer Immunotherapy at the University of Pennsylvania from 2011 to 20161
- A Ph.D. in Genetics, Genomics, and Systems Biology from the University of Chicago (2005-2011)1
- Dual Bachelor of Science degrees in Bioinformatics & Computational Biology and Biochemistry & Molecular Biology from the University of Maryland Baltimore County (2001-2005)1
Prior to his current role, he served as an Instructor-level Faculty at the University of Pennsylvania since April 2016, where he directed a laboratory designing novel cancer immunotherapies.1
Research Focus
Dr. Posey is known for his expertise in:
- CAR T cell technology
- GlycoCARs (a specific type of CAR T cell therapy)
- Developing immunotherapies for solid tumors
- Studying T cell exhaustion
- Exploring glycotargets in cancer treatment1
His work involves pre-clinical designs and evaluations of CAR T cell products within the Center for Cellular Immunotherapies at the Perelman School of Medicine, University of Pennsylvania.1
Professional Activities
Dr. Posey is actively involved in the scientific community:
- He ran for one of three SITC At-Large Director positions to address important issues in the cancer immunotherapy field3
- He participates in academic discussions, such as the 2024 Glyco-Immunology Webinar Series, where he led a discussion on the role of glycan biology in T-cell directed therapeutics4
Dr. Posey describes himself as an "all gas and no brakes" researcher, indicating his passionate and driven approach to his work.25 He is also involved in charitable activities, planning to run the 2024 Chicago Marathon on Team V to raise funds for innovative cancer research.5
Highlights
